DC-CIK Immunotherapy can kill residual cancer cells
Dendritic cell (DC) is the most powerful antigen-presenting cell in human body. It is the major antigen-presenting cell in innate immunity and play an important role in cancer suppression. Cytokine Induced Killer (CIK) is the lymphocyte, present in human blood, after a certain time to develop an immune active cells. Immune system is taken seriously more and more in the body against tumors. The DC-CIK cancer treatment Immunotherapy is called the fourth cancer treatment modality for this.
DC + CIK cells immune therapy is the most scientific method of treatment in patients with advanced cancer therapy of autoimmune cells, through advanced blood cell separator to extract the patient's own peripheral blood mononuclear cells, and high standards of GMP in the studio station, with a variety of cytokines induced by specific tumor antigen, the formation of activated The DC, CIK cells, both with training, can promote each other, so a lot of amplification, cell number and quality are significantly improved; the two re-order double output, but also their duties complement each other greatly improved Identify the body kill tumor cell function, to achieve better outcomes.
At present, clinical, cancer prognosis evaluation for the standard to 5-year survival after treatment for clinical cure standards. By a large number of domestic and international sample assessment of medical cases, DC + CIK treatment of autoimmune cell biology techniques, the prognosis for the situation, much higher than surgery alone or radiotherapy and chemotherapy clinical cure standards.
The DC-CIK cell therapy, cells with a precise role in killing tumor cells. In first developed, with high proliferative capacity and high cytotoxic activity of anti-tumor immune cells. Treatment of autoimmune cells CLS technology uses a unique dual-input dual-raising method, DC, CIK cells cultured double, double back to the transmission, clinical application to obtain a good therapeutic effect.